Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 54.5268
- Book/Share 17.633
- PB 44.8598
- Debt/Equity 2.4432
- CurrentRatio 1.3723
- ROIC 0.2572
- MktCap 745792413120.0
- FreeCF/Share 0.5421
- PFCF 1530.7726
- PE 63.6754
- Debt/Assets 0.4309
- DivYield 0.0071
- ROE 0.7692
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
Lilly Down More Than 15% in a Year: Time to Buy, Sell or Hold?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Eli Lilly Q2 preview: BofA sees focus on policy risks, obesity pipeline
Published: July 09, 2025 by: Proactive Investors
Sentiment: Positive
Bank of America on Wednesday reiterated its “Buy” rating and $1,000 price objective on Eli Lilly and Co (NYSE:LLY), ahead of the drugmaker's second-quarter earnings due on August 7, citing durable growth prospects and strong positioning in the obesity and diabetes markets. The bank made only minor adjustments to its revenue and earnings estimates through 2026, driven primarily by higher sales expectations for weight-loss drug Zepbound.
Read More
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
Published: July 08, 2025 by: CNBC
Sentiment: Neutral
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying he will "give people about a year, year and a half.
Read More
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
Read More
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's non-obesity drugs like Verzenio and Taltz are fueling sales growth as investor focus stays on GLP-1 blockbusters.
Read More
Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
CVS drops Lilly's Zepbound
Published: July 01, 2025 by: CNBC Television
Sentiment: Negative
CNBC's Angelica Peebles reports on news regarding CVS.
Read More
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
Published: June 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly edges ahead of Novo Nordisk as the stronger obesity bet, backed by robust sales growth, pipeline depth and strategic momentum.
Read More
Can LLY's Next-Generation Obesity Pipeline Fuel Further Growth?
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.
Read More
Lilly declares third-quarter 2025 dividend
Published: June 23, 2025 by: PRNewsWire
Sentiment: Neutral
INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on September 10, 2025, to shareholders of record at the close of business on August 15, 2025.
Read More
Eli Lilly and Company (LLY) Presents at Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference Transcript
Published: June 23, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Special Call (Lilly Investor Event at American Diabetes Association's (ADA) 85th Scientific Sessions) Conference June 22, 2025 7:30 PM ET Company Participants Jeffrey Emmick - Vice President of Diabetes Product Development Kenneth L Custer - Executive VP & President of Lilly Cardiometabolic Health Michael Czapar - Director of Investor Relations Ruth Gimeno - Corporate Participant Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexandria Janet Hammond - Wolfe Research, LLC Bryan Russell Dollinger - Leerink Partners LLC, Research Division Courtney Breen - Sanford C. Bernstein & Co., LLC.
Read More
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Published: June 22, 2025 by: PRNewsWire
Sentiment: Neutral
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS , June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used …
Read More
Final Trade: LLY, SHEL, USO, WMT
Published: June 20, 2025 by: CNBC Television
Sentiment: Neutral
The final trades of the day with the Fast Money traders.
Read More
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
Published: June 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer therapies.
Read More
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
Published: June 18, 2025 by: Benzinga
Sentiment: Positive
Scholar Rock SRRK revealed results on Wednesday from the Phase 2 EMBRAZE proof-of-concept trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.
Read More
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Read More
Eli Lilly is making it cheaper and easier to buy high doses of blockbuster weight-loss drug Zepbound
Published: June 17, 2025 by: Fast Company
Sentiment: Positive
Eli Lilly announced on Monday it will soon make the two highest doses of its popular weight-loss drug Zepbound available for self-paying customers on its website.
Read More
JBLU Cutting Back Flights, Solar Stocks Sell, LLY Bid for VERV
Published: June 17, 2025 by: Schwab Network
Sentiment: Negative
Breaking news hits Morning Trade Live with JetBlue (JBLU) cutting back flights after it reported weaker travel demand. Diane King Hall talks about the report and shares how it differs from its airline peers.
Read More
PFE or LLY: Which Is the Better Value Stock Right Now?
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Pfizer (PFE) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Read More
Want a $1 Million Retirement Portfolio? Invest $100,000 in These 3 Stocks and Wait 10 Years
Published: June 16, 2025 by: 24/7 Wall Street
Sentiment: Positive
Key Points in This Article: Growing a $100,000 investment into a $1 million retirement portfolio in 10 years requires a 25.9% CAGR from high-growth stocks with solid financials.
Read More
Lilly Moves Past 50-Day Average: Should You Buy the Stock Now?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Eli Lilly and Company LLY has reached a significant support level, making it an attractive option for investors from a technical standpoint. Earlier this week, the stock broke through its 50-day simple moving average (SMA), indicating a potential short-term bullish trend.
Read More
Can Mounjaro, Zepbound Help Lilly Maintain Dominance in Obesity Space?
Published: June 11, 2025 by: Zacks Investment Research
Sentiment: Positive
LLY banks on soaring Mounjaro and Zepbound sales to defend its obesity edge amid intensifying competition.
Read More
Drug pricing reform talks with US government lack clarity, industry executives say
Published: June 10, 2025 by: Reuters
Sentiment: Neutral
Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at an industry conference on Tuesday.
Read More
Eli Lilly and Company (LLY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript
Published: June 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Company Participants Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor Relations Conference Call Participants Unidentified Analyst Get started here.
Read More
Visa, Eli Lilly or Netflix— Which Stock Will Be A Trillion Dollar Company Next?
Published: June 09, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Justin Sullivan / Getty Images Visa Fintech is changing the world and Visa is at the center of it.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: June 09, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
Rare Outflow Signals Hit Eli Lilly Shares
Published: June 06, 2025 by: FXEmpire
Sentiment: Neutral
“Buy low, sell high” is a common investing mantra. It's easy to understand, but often hard to execute because emotion gets in the way.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000